Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human HGFR / c-MET Protein, Avi Tag (Avitag™), His tag, 200µg  

Recombinant Biotinylated Human HGFR / c-MET Protein, Avi Tag (Avitag™), His tag, 200µg

MABSol® Recombinant Biotinylated Human HGFR / c-MET Protein, expressed from human 293 cells (HEK293), Avi tag (Avitag™), His tag

Synonym
recombinant, human, biotinylated, protein, MET, HGFR, RCCP2, c-Met

More details

MET-H82E1-200

Availability: within 7 days

1 380,00 €

Background
Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.

Source
Biotinylated Human HGF R, Avitag,His Tag (MET-H82E1) is expressed from human 293 cells (HEK293). It contains AA Glu 25 - Thr 932 (Accession # AAI30421.1).
Predicted N-terminus: Glu 25 (α chain) & Ser 308 (β chain)

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 104.3 kDa. The protein migrates as 40-45 kDa α subunit and 80 kDa β subunit under reducing (R) condition (SDS-PAGE) due to glycosylation.
The mature form of HGFR is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Reconstitute at 200 μg/mL in sterile deionized water.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

References

(1) Bottaro DP, et al., 1991, Science 251 (4995): 802–4.
(2) Galland F, et al., 1992, Cytogenet. Cell Genet. 60 (2): 114–6.
(3) Cooper CS, 1992, Oncogene 7 (1): 3–7.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.